Executive Director, Radiology & Theranostics

Role: Lead the global Radiology & Theranostics organization to develop and execute imaging strategies across oncology programs from preclinical through late-phase clinical trials. Responsibilities include establishing a unified operating model, leading imaging strategies for patient selection, target validation, pharmacodynamics, and endpoints, and advancing imaging-based biomarkers and radiomics. The role integrates multiple disciplines—translational radiology, computational radiology, medical physics, and nuclear medicine—and collaborates with external academic and regional partners. Requirements: MD, PhD, or equivalent in radiology, nuclear medicine, or related fields; 10+ years in pharmaceutical development, translational medicine, or imaging sciences; expertise in clinical imaging endpoints, biomarkers, radiomics, and theranostics; strong understanding of oncology drug development, regulatory expectations, and global teams leadership. Preferred qualifications include experience with oncology solid tumors and hematologic malignancies, therapy modalities, and early to late clinical development phases. High-value specifics involve leading imaging strategies in oncology, with a focus on biomarkers, radiomics, and theranostics, including dosimetry and radioconjugate imaging, spanning from preclinical to Phase III. The position reports to senior leadership, with a focus on strategic planning, scientific innovation, and cross-functional collaboration. Location options include Gaithersburg MD or Kendall Square MA, with regional and external collaborations, and no explicit travel requirements stated.